8-guanidino-octanoic acid | 58185-61-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 8-guanidino-octanoic acid
• 英文别名: 8-guanidinooctanoic acid；8-(diaminomethylideneamino)octanoic acid
• CAS: 58185-61-8
• 化学式: C₉H₁₉N₃O₂
• 分子量: 201.269
• InChiKey: FPYQJFXRONSSLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  362.4±44.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-guanidino-octanoic acid 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 三乙胺 作用下， 以 甲醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、379.21 kPa 条件下， 反应 15.0h， 生成 N,N'-bis-(8-guanidino)octanoyl-3,3-diaminopropionic acid
  参考文献：
  名称：

  Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg

  摘要：

  A series of nonpeptide fibrinogen receptor antagonists based upon the tetrapeptide Arg-Gly-Asp-Arg were prepared. These relatively simple derivatives incorporate a high degree of conformational flexibility that was anticipated to allow them to attain the requisite conformation for binding to the platelet fibrinogen receptor. Optimization of the distances between the required acidic and basic functional groups led eventually to compound 7, which is a one hundred-fold more potent inhibitor of platelet aggregation than the peptide it is based upon.

  DOI：

  10.1016/s0223-5234(99)80069-5
• 作为产物：
  描述：

  8-氨基辛酸 、 氨基亚氨基甲烷磺酸 在 potassium carbonate 作用下， 以 水 为溶剂， 生成 8-guanidino-octanoic acid
  参考文献：
  名称：

  Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg

  摘要：

  A series of nonpeptide fibrinogen receptor antagonists based upon the tetrapeptide Arg-Gly-Asp-Arg were prepared. These relatively simple derivatives incorporate a high degree of conformational flexibility that was anticipated to allow them to attain the requisite conformation for binding to the platelet fibrinogen receptor. Optimization of the distances between the required acidic and basic functional groups led eventually to compound 7, which is a one hundred-fold more potent inhibitor of platelet aggregation than the peptide it is based upon.

  DOI：

  10.1016/s0223-5234(99)80069-5

文献信息

• Indolyl platelet-aggregation inhibitors
  申请人：Monsanto Co.

  公开号：US05037808A1

  公开（公告）日：1991-08-06

  Novel peptide mimetic compounds are provided which have useful activity as inhibitors of platelet aggregation. These compounds have the chemical structure ##STR1## wherein x=4 to 8, y=0 to 4, W=CH.sub.2 --CH.sub.2 or CH.dbd.CH, Z=H, COOH, CONH.sub.2, CH.sub.2 OH, CO.sub.2 R, CH.sub.2 OR or C.sub.1-6 alkyl, R=C.sub.1-6 alkyl, Ar=a nitrogen-containing heterocyclic group, and Asp=aspartic acid residue.

  提供了一种新型的肽类模拟化合物，其作为血小板聚集抑制剂具有有用的活性。这些化合物具有化学结构##STR1##其中x=4至8，y=0至4，W=CH.sub.2 --CH.sub.2或CH.dbd.CH，Z=H，COOH，CONH.sub.2，CH.sub.2 OH，CO.sub.2 R，CH.sub.2 OR或C.sub.1-6烷基，R=C.sub.1-6烷基，Ar=氮含杂环基团，Asp=天冬氨酸残基。
• GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF
  申请人：Academia Sinica

  公开号：US20200291071A1

  公开（公告）日：2020-09-17

  Disclosed herein are novel compounds and uses thereof. The present compounds are useful in suppressing the growth of various bacteria, including gram-positive and gram-negative bacteria. Accordingly, these compounds may be used to manufacture a medicament or pharmaceutic composition for treating disease and/or disorders associated with bacterial infection, especially antibiotic-resistant bacterial infection. Al so disclosed herein are methods for treating infectious diseases by use of the present compounds, medicament or pharmaceutical composition.

  本文披露了新颖的化合物及其用途。这些化合物可用于抑制各种细菌的生长，包括革兰氏阳性和阴性细菌。因此，这些化合物可用于制造治疗与细菌感染有关的疾病和/或疾病的药物或药学组合物，特别是抗生素耐药性细菌感染。本文还披露了利用这些化合物、药物或药学组合物治疗传染病的方法。
• Novel platelet-aggregation inhibitors
  申请人：Mosanto Company

  公开号：US04879313A1

  公开（公告）日：1989-11-07

  Novel peptide mimetic compounds are provided which have useful activity as inhibitors of platelet aggregation. These compounds have the chemical structure ##STR1## wherein x=6 to 10, y=0 to 4, Z=H, COOH, CONH.sub.2 or C.sub.1-6 alkyl, Ar=phenyl, biphenyl or napthyl, each substituted with 1 to 3 methoxy groups, or an unsubstituted phenyl, biphenyl, napthyl, pyridyl or thienyl group, and Asp=aspartic acid residue.

  提供了新型肽类模拟化合物，其作为血小板聚集抑制剂具有有用的活性。这些化合物具有化学结构##STR1##其中x = 6至10，y = 0至4，Z = H，COOH，CONH.sub.2或C.sub.1-6烷基，Ar =苯基，联苯或萘基，每个取代1至3个甲氧基或未取代的苯基，联苯，萘基，吡啶基或噻吩基，Asp =天冬氨酸残基。
• Antithrombotic diaminoalkanoic acid derivatives
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05258398A1

  公开（公告）日：1993-11-02

  This invention relates to novel diaminoalkanoic acid derivatives that inhibit platelet aggregation and thrombus formation in mammalian blood thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease and disseminated intravascular coagulation, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

  本发明涉及新型二氨基烷基酸衍生物，其可抑制哺乳动物血液中的血小板聚集和血栓形成，因此在预防和治疗与疾病状态相关的血栓形成方面具有用途，例如心肌梗死、中风、周围动脉疾病和弥漫性血管内凝血，并且涉及包括这些化合物的制药组合物以及它们在哺乳动物中抑制血栓形成和血小板聚集的使用。
• Novel platelet-aggregation inhibitor
  申请人：Monsanto Company

  公开号：US05053393A1

  公开（公告）日：1991-10-01

  N-[8-[(Aminoiminomethyl)amino]-1-oxooctyl]-N-L-.alpha.-aspartyl-L-phenylani ne is disclosed as a highly potent inhibitor of platelet aggregation.

  N-[8-[(氨基亚甲基)氨基]-1-氧代辛基]-N-L-.alpha.-天冬氨酸-L-苯丙氨酸被披露为一种高效的血小板聚集抑制剂。